AI Breast Triage Tool Wins First-Ever Regulatory Approval for Independent Use
A South Korean AI radiology company called Lunit has become the first in the world to receive regulatory approval for a breast cancer screening tool that can operate without a radiologist's prior review of the images.
The tool, Lunit INSIGHT MMG, is designed to triage mammograms by flagging suspicious cases for prioritized radiologist review. Until now, AI screening tools have acted as secondary readers—assisting radiologists after they have already examined images. This approval marks a shift toward AI functioning as a primary filter in the diagnostic pipeline.
Regulatory clearance for standalone AI triage differs from earlier approvals because it assigns the algorithm a more autonomous role in patient care workflows. The approval was granted based on clinical validation data demonstrating the tool's ability to accurately identify lesions warranting further investigation.
The company says this capability could help address radiologist shortages and reduce turnaround times for results in high-volume screening programs. However, the tool remains intended to support rather than replace clinical judgment, with final diagnoses still requiring radiologist oversight.
The approval is expected to pave the way for similar AI triage solutions across other imaging modalities, as regulators increasingly define pathways for autonomous AI deployment in healthcare settings.